Highest-materiality recent filing
Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity
Reported stockholders' equity of $1.895M as of March 31, 2026, below Nasdaq's $2.5M minimum.
Tenon Medical Q1 2026 revenue $1.4M (+90% YoY), gross margin expands to 68.5%
Revenue $1.4M, up ~90% YoY from $0.7M; gross profit $0.9M, up ~193% YoY.
Q4 revenue $1.5M (+92% YoY); gross margin improved to 69% from 46%.
Tenon Medical closes $4.3M private placement of senior convertible notes
Aggregate gross proceeds of $4.3M from senior convertible promissory notes with 20% original issue discount.
Nasdaq letter dated Feb 25, 2026: common stock failed to maintain $1.00 bid price for 30 consecutive business days.
Tenon Medical pre-announces Q4 2025 revenue ~$1.5M (+90% YoY); FY 2025 rev ~$3.9M (+20%)
Preliminary Q4 2025 revenue of $1.45M-$1.48M (unaudited), ~90% increase year-over-year.
Tenon Medical closes $2.85M PIPE offering of 2.2M shares and warrants at $1.285/unit
Issued 2,217,904 shares and warrants to purchase same number at combined $1.285/unit; warrants exercisable at $1.16 for 3 years.
Acquired substantially all assets of SiVantage (SImmetry) and SIMPL Medical on Aug 1, 2025, for cash, stock, and royalties.
Tenon Medical raises $2.5M in registered direct offering and private placement at $2.00/share
Registered direct offering of 1,271,500 shares (or equivalents) at $2.00/share raising ~$2.5M.
Tenon Medical raises ~$1.46M in registered direct offering and private placement at $2.00/share
Gross proceeds ~$1.46M from 733,500 shares (or equivalents) at $2.00/share in registered direct offering.
Tenon Medical enters warrant inducement; existing warrants exercised at $1.25, ~$3M gross proceeds
Existing warrants for 2,445,700 shares exercised at reduced exercise price of $1.25 per share, down from $4.28.
Tenon Medical regains Nasdaq minimum equity compliance after raising ~$9.6M
Received Nasdaq notice on Aug 23, 2024 for non-compliance with $2.5M minimum stockholders' equity (reported $832K as of June 30).
Tenon Medical closes $4.5M public offering of shares and warrants at $3.68/unit
Issued 1,222,850 shares (or pre-funded warrants) plus warrants for 1,222,850 shares at $3.68 per unit.
Nasdaq notified Tenon on Sept 9, 2024, that publicly held shares of 490,364 are below the 500,000 minimum required by Listing Rule 5550(a)(4).
Tenon Medical raises $550K via Series B Preferred Stock and warrant private placement
Aggregate offering price of $550,000 for 86,454 Series B Preferred shares and warrants to buy 16,214 common shares at $4.2756.
Tenon Medical receives Nasdaq delisting notice for failing minimum equity requirement
Stockholders' equity of $832k as of June 30, 2024, below Nasdaq's $2.5M minimum requirement.
Tenon Medical CFO Steven Van Dick to retire effective July 31, 2024
CFO Steven Van Dick to resign effective July 31, 2024; will consult post-resignation.
Tenon Medical receives Nasdaq bid price deficiency notice; stock below $1.00 for 30 days
Nasdaq letter dated May 7, 2024, citing 30 consecutive business days below $1.00 minimum bid price from Mar 25 to May 6.
On August 20, 2024, Tenon Medical, Inc. (the “Company”) entered into an offer letter (the “Letter”) with Kevin Williamson pursuant to which Mr. Williamson was appointed as Chief Financial Officer of the Company, effective as of September 3, 2024.
Steven Van Dick informed Tenon Medical, Inc. (the “Company”) of his decision to retire and as a result, is resigning from his positions as Executive Vice President, Finance and Administration, Chief Financial Officer and Assistant Secretary effective as of July 31, 2024.
Max materiality 0.85 · Median 0.65 · Most common event other_material